67831-84-9

Basic information

• Product Name: 3-sulfanylidene-2,4,9-triazabicyclo[4.3.0]nona-7,10-dien-5-one
• Synonyms: 2-Mercapto-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one AldrichCPR;3-sulfanylidene-2,4,9-triazabicyclo[4.3.0]nona-7,10-dien-5-one;Nsc25976;2-Mercapto-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one;3,7-Dihydro-2-sulphanyl-4H-pyrrolo[2,3-d]pyrimidin-4-one, 3,7-Dihydro-2-mercapto-4H-pyrrolo[2,3-d]pyrimidin-4-one;3,7-Dihydro-2-thio-4H-pyrrolo[2,3-d]pyrimidin-4-one;1,2,3,7-Tetrahydro-2-thioxo-4H-pyrrolo[2,3-d]pyriMidin-4-one;2-Thioxo-7-deazahypoxanthine
• CAS NO: 67831-84-9
• Molecular Formula: C₆H₅N₃OS
• Molecular Weight: 167.191
• Product Categories: Bases & Related Reagents;Intermediates;Nucleotides
• Mol File: 67831-84-9.mol
• Article Data: 7

Chemical Properties

• Melting Point: 335-345°C dec.
• Appearance: /
• Density: 1.65g/cm³
• Refractive Index: 1.778
• PKA: 9?+-.0.20(Predicted)
• CAS DataBase Reference: 3-sulfanylidene-2,4,9-triazabicyclo[4.3.0]nona-7,10-dien-5-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-sulfanylidene-2,4,9-triazabicyclo[4.3.0]nona-7,10-dien-5-one(67831-84-9)
• EPA Substance Registry System: 3-sulfanylidene-2,4,9-triazabicyclo[4.3.0]nona-7,10-dien-5-one(67831-84-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 67831-84-9(Hazardous Substances Data)

Usage

Chemical Properties

Colourless Crystalline Solid

Uses

Activator of Xanthine oxidase

InChI:InChI=1/C6H5N3OS/c10-5-3-1-2-7-4(3)8-6(11)9-5/h1-2H,(H3,7,8,9,10,11)

Upstream product

• 7400-05-7 6-amino-5-(2,2-diethoxy)-2-mercaptopyrimidine-4-ol 
• 52133-67-2 ethyl 2-cyano-4,4-diethoxybutyrate 
• 17356-08-0 thiourea 
• 7400-05-7 6-amino-5-(2,2-diethoxyethyl)-2-thioxo-2,3-dihydropyrimidin-4(1H)-one 

Downstream Products

• 3680-71-5 1H-pyrrolo[2,3-d]pyrimidin-4(7H)-one 
• 123148-78-7 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine 
• 3680-71-5 Allopurinol 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 57564-94-0 2-(methylthio)-4-chloropyrrolo<2,3-d>pyrimidine 
• 3680-71-5 7-deazahypoxanthine 
• 156124-78-6 4-chloro-7-[3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-β-D-erythro-pentofuranosyl]-7H-pyrrolo[2,3-d]pyrimidine 
• 1440537-02-9 4-chloro-7-[3,5-di-O-benzoyl-2-deoxy-2,2-difluoro-β-D-erythropentofuranosyl]-5-iodopyrrolo[2,3-d]pyrimidine 
• 1252858-45-9 (2R,3R,4R,5R)-5-((benzoyloxy)methyl)-2-(4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-methyltetrahydrofuran-3,4-diyl dibenzoate 

Relevant articles and documents

NEW COMPOUND HAVING FGFR INHIBITORY ACTIVITY AND PREPARATION AND APPLICATION THEREOF

The present invention relates to a new compound having an FGFR inhibitory activity and preparation and application thereof. In particular, the compound according to the present invention has a structure as shown in formula I, wherein each group and substituent are as defined in the description. Also disclosed in the present invention are a preparation method for the compound and a use thereof in preparation of a drug for treating and/or preventing a tumor-related disease and/or an FGFR-related disease.

Synthetic method of 4-chloropyrrolopyrimidine

The invention relates to a synthetic method of 4-chloropyrrolopyrimidine. The synthetic method takes ethyl cyanoacetate, bromoacetaldehyde diethyl acetal, thiourea, sodium ethoxide and hydrogen peroxide as raw materials and takes DMF, ethanol, water and phosphorous oxychloride as solvents to obtain the target product 4-chloropyrrolopyrimidine through four steps of reactions. The method improves amethod of removing a mercapto group in a third step. The mercapto group is first oxidized to sulfinic acid by using the hydrogen peroxide and then is removed under acidic conditions. The method is mild in reaction conditions, safe in operation and high in yield, is environmentally friendly, and is suitable for industrial production.

Pre-steady state kinetic analysis of cyclobutyl derivatives of 2′-deoxyadenosine 5′-triphosphate as inhibitors of HIV-1 reverse transcriptase

Pre-steady state kinetic analysis was utilized for biochemical evaluation of a series of cyclobutyl adenosine nucleotide analogs with HIV-1 RT WT. The phosphonyl-diphosphate form of the cyclobutyl nucleotide, 5, was the most efficiently incorporated of the series. Nucleotide 5 was fourfold more efficiently incorporated than the FDA approved TFV-DP by RTWT. The kinetics of incorporation for 5 using the drug resistant mutant enzyme K65R was also determined. Compound 5 was threefold more efficiently incorporated compared to TFV-DP with RTK65R. These results demonstrate cyclobutyl adenosine analogs can act as substrates for incorporation by HIV-1 RT and be a potential scaffold for HIV inhibitors.